- Company
- Otsuka is setting new records for sales & operating profit
- by An, Kyung-Jin Apr 6, 2020 06:27am
- Korea Otsuka Pharmaceutical has achieved the best performance since its launch last year. Although the sales of healthcare products were low due to the boycott of Japanese-made products, sales of professional medicines surged, setting new records for both sales and operating profit According to the audit report of Korea Otsuka Pharmaceutical,
- Policy
- FDA requests removal of all Ranitidines from the market
- by Lee, Tak-Sun Apr 6, 2020 06:27am
- As the Food and Drug Administration (FDA) decides to withdraw all products containing Ranitidine on the 1st, domestic pharmaceutical companies seeking to resume sales are embarrassed Until recently, some Ranitidine products were on sale in the US market, so it was expected that if the stability data were submitted in Korea, it would be po
- Company
- GC Pharma: all capacity focused on COVID-19
- by Kim, Jin-Gu Apr 6, 2020 06:26am
- The GC Corporations Group says ‘all hands on deck’ to fight against COVID-19. The group has a plan to cover all&8212;from diagnostics to preventive and treatment&8212;with the group’s test kit, vaccine and specialized treatment. On Apr. 2, GC Pharma disseminated a press release and announced “The company would commercialize a plas
- Policy
- The first generic for Afinitor & Betmiga will be released
- by Lee, Tak-Sun Apr 6, 2020 06:26am
- Guangdong Pharmaceutical is licensed for the first generic version of the breast cancer treatment drug Afinitor (Everolimus, Novartis) and is expected to launch this year. In addition, Hanmi Pharm and Chong Kun Dang also received the first generic approval of the overactive bladder treatment drug 'Betmiga' (Mirabegron, Astellas). These pro
- Company
- KRPIA demands transferred originals evade pricing reduction
- by Eo, Yun-Ho Apr 3, 2020 06:36am
- The pharmaceutical industry is firmly opposing to the Korean government’s decision to apply stepped pricing system on transferred original drugs. Sources reported Korean Research-based Pharmaceutical Industry Association (KRPIA) has delivered an official statement to Health Insurance Review and Assessment Service (HIRA) on Apr. 2, deman
- Policy
- Will Hanmi and Chong Kun Dang's generic exclusivity effect?
- by Lee, Tak-Sun Apr 3, 2020 06:35am
- It is noteworthy whether Hanmi Pharm or Chong Kun Dang among the domestic pharmaceutical companies will be able to achieve the performance in the market while acquiring generic exclusivity, which is the most outstanding pharmaceutical company. In particular, attention has been focused on Hanmi and Chong Kun Dang in that there are no succes
- Company
- FMC-Korea, names Hee-gyeong Kim as new CEO
- by An, Kyung-Jin Apr 3, 2020 06:34am
- FMC Korea has replaced its representative for the first time since its establishment in Korea. FMC Korea said that it has appointed Hee-gyeong Kim as the new chief executive officer effective on April 1. This is the first time the company has replaced the CEO since the establishment of a domestic corporation in 1997. Former CEO Seong-ok
- Product
- Does Tylenol prevent COVID-19 infection?
- by Kim JiEun Apr 3, 2020 06:34am
- Tylenol stockpiles are showing signs of prolongation which were initiated by the World Health Organization (WHO) According to pharmacies on the 1st, there are more customers who want to buy Tylenol, and many of them want to buy in bulk. Tylenol's full-scale hoarding began after WHO recently advised patients with suspicion of COVID-19 to
- Policy
- Rumor: Chief Yang as new Pharmaceutical Benefits Director
- by Kim, Jung-Ju Apr 3, 2020 06:33am
- Apparently, a rumor is circulating about the new director of Pharmaceutical Benefits Division at Ministry of Health and Welfare (MOHW), who would lead the Moon Jae-in Care-initiated drug pricing system revision. According to pharmaceutical industry sources on Mar. 31, Chief Yang Yoon Seok of Smart Healthcare Regulation Revision Planning
- Policy
- New drug reimbursement review costs KRW 39 million
- by Lee, Hye-Kyung Apr 2, 2020 06:26am
- Experts recommend the Korean government should review implementing service fee system for reimbursement review to enhance speed and efficiency of pharmaceutical reimbursement listing procedure, and to provide quality service through sufficient financial and human resources. While the Health Insurance Review and Assessment Service (HIRA) does
